sPLA2 inhibition to decrease enzyme release after PCI trial (SPIDER-PCI).

Trial Profile

sPLA2 inhibition to decrease enzyme release after PCI trial (SPIDER-PCI).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2012

At a glance

  • Drugs Varespladib (Primary)
  • Indications Myocardial infarction; Myocardial reperfusion injury
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SPIDER-PCI
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 15 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top